New Treatment Options for Cervical and Ovarian Cancer: Promising Findings from ASCO ’23

CANCER in the pelvis or pelvis there are several types. These include cervical cancer and ovarian cancer. Recently research revealed a promising treatment for this type of cancer of the pelvis.

Brown University professor of medicine and surgery Don Dizon who specializes in the treatment of hip cancer, recently attended the American Society of Clinical Oncology or ASCO ’23 seminar and shared some of the exciting new findings from the study presented at the conference.

One study, called the SHAPE Trial, looked at the treatment of early cervical cancer. Traditionally the way of treatment is with a complicated surgical procedure called a radical hysterectomy. This complicated surgery is used to remove the cervix and uterus, as well as extending the pelvic sidewall.

However, the study found that the simpler procedure, removing only the cervix and uterus, had the same three-year survival outcomes and better quality of life, especially with regard to sexual quality of life.

Also read:

Study Reveals Cancer’s Unlimited Ability To Evolve

Another study presented at ASCO ’23 looked at the treatment of metastatic cervical cancer. Women with cervical cancer that had spread were randomly assigned to standard treatment with chemotherapy with or without bevacizumab, a drug that blocks certain proteins, and with or without pembrolizumab, a checkpoint inhibitor.

The study found that adding pembrolizumab increased overall survival by about one year, suggesting that chemotherapy with pembrolizumab plus or minus bevacizumab is the new standard of care for people living with metastatic cervical cancer.

Another study, the MIRASOL trial looked at treatment of recurrent ovarian cancer that returned early after trying treatment with a combination of platinum and taxane. This condition is called platinum resistance.

The study treated people with platinum-resistant ovarian cancer with a new drug called mirvetuximab or standard chemotherapy.

The study found that mirvetuximab improved overall survival over standard-care chemotherapy in a select group of people whose tumors expressed a protein called folate receptor alpha.

Also read:

Hysterectomy Helps Women with Cervical Cancer

For those with high-expression folate receptor alpha ovarian cancer whose disease relapses early after chemotherapy, mirvetuximab may be a new treatment option that can improve overall survival.

Overall, the study presented at ASCO ’23 offers new hope and treatment options for those living with cervical and ovarian cancer.

The findings suggest that simpler procedures and new drugs can improve survival and quality of life, making a significant impact on the lives of those affected by this cancer. (aru)

Also read:

Sleep Disorders Increase Stroke Risk